RxDoctor Payments Data

Ki Deuk Wohlfert

Nurse Practitioner · Auburn, WANPI 1679610885

Payments from drug & device makers

$1,528in general payments, 2019–2025

Across 56 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$374
  • AbbVie$235
  • Bayer$121
  • Boehringer Ingelheim$97
  • Nestle Healthcare Nutrition Inc.$93
  • Aimmune Therapeutics, Inc.$89
  • plus $520 from 14 others

What the payments were for

  • Food & beverage$1,20379%
  • Education$32521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,528 in reported general payments places this provider in the 90th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$28,514
Medicare patients
71
Services billed
753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin379$393,828
ProliaDenosumab92$161,008
ZenpepLipase/Protease/Amylase104$159,410
CreonLipase/Protease/Amylase130$157,972
JanuviaSitagliptin Phosphate102$118,840
VascepaIcosapent Ethyl151$72,659
MyrbetriqMirabegron80$61,425
TradjentaLinagliptin38$45,100
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$45,029
JanumetSitagliptin Phos/Metformin Hcl45$44,197
RexultiBrexpiprazole27$42,268
RestasisCyclosporine56$38,466
EliquisApixaban44$37,199
XareltoRivaroxaban55$35,218
LinzessLinaclotide44$29,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$97$444,387429 claims
AbbVieCreon, Restasis, Linzess$235$225,831230 claims
AmgenProlia$14$161,00892 claims
Aimmune Therapeutics, Inc.Zenpep$89$159,410104 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Shingrix$47$75,609154 claims
Astellas Pharma US IncMyrbetriq$374$61,42580 claims
PfizerEliquis$45$37,19944 claims
Novo NordiskRybelsus, Ozempic$22$36,06032 claims
Johnson & JohnsonXarelto$66$35,21855 claims
Lilly USA, LLCTrulicity$33$27,52325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Auburn

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →